Author

Y.-F. Kang

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

C. Sun· 1 shared C.-W. Ke· 1 shared G.-K. Feng· 1 shared J.-C. Zhao· 1 shared J.-P. Li· 1 shared M. Xu· 1 shared M.-S. Zeng· 1 shared N.-S. Zhong· 1 shared

Activity by Year

2020-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

C. Sun

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Rapid development of SARS-CoV-2 receptor binding domain-conjugated nanoparticle vaccine candidate

Y.-F. Kang, C. Sun, Z. Zhuang, R.-Y. Yuan, Q.-B. Zheng, P.-P. Zhou, J.-P. Li, X.-C. Chen, X. Zhang, X.-H. Yu, X.-W. Kong, Q.-Y. Zhu, M. Xu, N.-S. Zhong, Y.-X. Zeng, , M.-S. Zeng

This study designs and tests RBD-conjugated nanoparticle vaccines against SARS-CoV-2, showing enhanced neutralizing activity compared to monomeric RBD.

bioRxiv · Nov 3, 2020 · PreprintMicrobiology